"The cornerstone of Covenant Health’s cancer care program is Joe Arrington Cancer Research and Treatment Center. This center of excellence brings world-class cancer care to the West Texas and Eastern New Mexico region. We are a team of surgeons, medical oncologists, radiation oncologists, radiation therapists, experienced oncology nurses and pharmacists, along with other cancer specialists who work together to provide a multidisciplinary approach while caring for the whole person – body, mind and spirit."

During the past decade, Joe Arrington Cancer Research and Treatment Center conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 41 clinical trials were completed, i.e. on average, 146.4% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 18 clinical trials were completed. i.e. 163.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Joe Arrington Cancer Research and Treatment Center" #1 sponsor was "Radiation Therapy Oncology Group" with 38 trials, followed by "NSABP Foundation Inc" with 18 trials sponsored, "Celgene" with 6 trials sponsored, "Bristol-Myers Squibb" with 5 trials sponsored and "Eli Lilly and Company" with 5 trials sponsored. Other sponsors include 57 different institutions and companies that sponsored additional 51 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Joe Arrington Cancer Research and Treatment Center" #1 collaborator was "National Cancer Institute (NCI)" with 60 trials as a collaborator, "NRG Oncology" with 7 trials as a collaborator, "North Central Cancer Treatment Group" with 5 trials as a collaborator, "SWOG Cancer Research Network" with 5 trials as a collaborator and "Cancer and Leukemia Group B" with 4 trials as a collaborator. Other collaborators include 47 different institutions and companies that were collaborators in the rest 44 trials.

According to Clinical.Site data, the most researched conditions in "Joe Arrington Cancer Research and Treatment Center" are "Breast Cancer" (25 trials), "Lung Cancer" (14 trials), "Head and Neck Cancer" (9 trials), "Prostate Cancer" (8 trials) and "Brain and Central Nervous System Tumors" (5 trials). Many other conditions were trialed in "Joe Arrington Cancer Research and Treatment Center" in a lesser frequency.

Most popular intervention types in "Joe Arrington Cancer Research and Treatment Center" are "Drug" (113 trials), "Radiation" (43 trials), "Biological" (19 trials), "Procedure" (19 trials) and "Other" (5 trials). Other intervention types were less common.

The name of intervention was led by "radiation therapy" (32 trials), "cisplatin" (10 trials), "paclitaxel" (9 trials), "Placebo" (8 trials) and "conventional surgery" (8 trials). Other intervention names were less common.

The vast majority of trials in "Joe Arrington Cancer Research and Treatment Center" are 103 trials for "All" genders, 24 trials for "Female" genders and 7 trials for "Male" genders.

Currently, there are NaN active trials in "Joe Arrington Cancer Research and Treatment Center". undefined are not yet recruiting, 5 are recruiting, 19 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 90 completed trials in Joe Arrington Cancer Research and Treatment Center, undefined suspended trials, and 16 terminated clinical trials to date.

Out of the total trials that were conducted in Joe Arrington Cancer Research and Treatment Center, 15 "Phase 1" clinical trials were conducted, 56 "Phase 2" clinical trials and 69 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".